NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA
— Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047)— Median overall survival of 26.09 months; 86.7% of patients alive at
NeOnc's medicine for brain tumors worked better than expected in testing, hitting its main goal. When a medicine passes important tests like this, it's a sign the company might be on track to help patients and grow—worth watching how the FDA responds next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.